RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
BMC CANCER
Collezione AOU San Luigi di Orbassano

Items : 11

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial. in BMC cancer / BMC Cancer. 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2.

2023
AOU San Luigi di Orbassano

Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S;

Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling. in BMC cancer / BMC Cancer. 2022 Nov 24;22(1):1212. doi: 10.1186/s12885-022-10296-x.

2022
AOU San Luigi di Orbassano

Caccialanza R; Cereda E; Agustoni F; Klersy C; Casirati A; Montagna E; Carnio S; Novello S; Milella M; Pilotto S; Trestini I; Buffoni L; Ferrari A; Pedrazzoli P;

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study. in BMC cancer / BMC Cancer. 2022 Aug 24;22(1):915. doi: 10.1186/s12885-022-10018-3.

2022
AOU San Luigi di Orbassano

Celio L; Cortinovis D; Cogoni AA; Cavanna L; Martelli O; Carnio S; Collovà E; Bertolini F; Petrelli F; Cassano A; Chiari R; Zanelli F; Pisconti S; Vittimberga I; Letizia A; Misino A; Gernone A; Bonizzoni E; Pilotto S; De Placido S; Bria E;

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. in BMC cancer / BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

2019
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Ciuffreda L; Basso M; Catalano V; Bracarda S; Verusio C; Maiello E; Cinieri S; Giuliani F; Tassinari D; Frassineti GL; Spallanzani A; Bonetti A; Tortora G; Scagliotti G; Pinotti G; Tomasello G; Bertolini A; Zaniboni A; Longarini R; Luporini AG; Rimassa L; Di Costanzo F; Cardellino GG; Scartozzi M; Berardi R; Di Donato S; Lonardi S; Tamberi S; Antista M; et alii...

Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients. in BMC cancer / BMC Cancer. 2018 Nov 12;18(1):1094. doi: 10.1186/s12885-018-5022-1.

2018
AOU San Luigi di Orbassano

Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A;

Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review. in BMC cancer / BMC Cancer. 2018 Mar 20;18(1):311. doi: 10.1186/s12885-018-4205-0.

2018
AOU San Luigi di Orbassano

Brizzi MP; La Salvia A; Tampellini M; Sonetto C; Volante M; Scagliotti GV;

FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report. in BMC cancer / BMC Cancer. 2018 Apr 26;18(1):470. doi: 10.1186/s12885-018-4395-5.

2018
AOU San Luigi di Orbassano

Zichi C; Tampellini M; Tucci M; Sonetto C; Baratelli C; Brizzi MP; Scagliotti GV;

The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase. in BMC cancer / BMC Cancer. 2016 May 16;16:314. doi: 10.1186/s12885-016-2346-6.

2016
AOU San Luigi di Orbassano

Crivellaro S; Carrà G; Panuzzo C; Taulli R; Guerrasio A; Saglio G; Morotti A;

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. in BMC cancer / BMC Cancer. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0.

2016
AOU San Luigi di Orbassano

Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G;

Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature. in BMC cancer / BMC Cancer. 2015 Nov 18;15:914. doi: 10.1186/s12885-015-1923-4.

2015
AOU San Luigi di Orbassano

Brizzi MP; Sonetto C; Tampellini M; Di Maio M; Volante M; Scagliotti GV;

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. in BMC cancer / BMC Cancer. 2009 Nov 3;9:388. doi: 10.1186/1471-2407-9-388.

2009
AOU San Luigi di Orbassano

Brizzi MP; Berruti A; Ferrero A; Milanesi E; Volante M; Castiglione F; Birocco N; Bombaci S; Perroni D; Ferretti B; Alabiso O; Ciuffreda L; Bertetto O; Papotti M; Dogliotti L;